Related Experiment Videos
[Evoked potentials with intrathecal and systemic corticosteroid therapy in multiple sclerosis]
1Neurologische Abteilung, Universitäts-Nervenklinik Homburg/Saar.
EEG-EMG Zeitschrift Fur Elektroenzephalographie, Elektromyographie Und Verwandte Gebiete
|June 1, 1989
Summary
Steroid treatment for multiple sclerosis (MS) patients did not significantly alter visual or somatosensory evoked potentials. Clinical assessments using the Expanded Disability Status Scale (EDSS) showed improvements, suggesting evoked potentials are inadequate for short-term MS trials.
Area of Science:
- Neuroscience
- Clinical Neurology
- Medical Research
Background:
- Multiple Sclerosis (MS) is a chronic neurological disease.
- Assessing treatment efficacy in MS requires reliable biomarkers.
- Evoked potentials (EPs) are electrophysiological measures of neural pathway function.
Purpose of the Study:
- To evaluate the utility of visual evoked potentials (VEPs) and somatosensory evoked potentials (SEPs) for short-term assessment of steroid therapy in MS patients.
- To compare changes in EPs with clinical status using the Expanded Disability Status Scale (EDSS).
Main Methods:
- 46 MS patients received systemic or intrathecal steroid treatment.
- VEPs and SEPs were measured before and three weeks after treatment initiation.
- Clinical status was assessed using the EDSS.
Main Results:
- Only one patient exhibited significant changes in VEP latencies.
- SEP latencies remained largely unchanged before and after steroid therapy.
- Clinical examination revealed EDSS improvements in 24 out of 46 patients.
Conclusions:
- VEPs and SEPs are not adequate tools for short-term efficacy assessment in MS therapeutic trials.
- Clinical outcomes measured by EDSS showed more sensitivity to short-term steroid treatment than evoked potentials.
- Further research is needed to identify reliable electrophysiological biomarkers for MS treatment monitoring.